Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) insider Nicholas Hollmeyer Lynton sold 5,956 shares of the company’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $7.95, for a total transaction of $47,350.20. Following the transaction, the insider now owns 78,593 shares of the company’s stock, valued at approximately $624,814.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Nicholas Hollmeyer Lynton also recently made the following trade(s):
- On Tuesday, April 23rd, Nicholas Hollmeyer Lynton sold 276 shares of Cardlytics stock. The shares were sold at an average price of $12.76, for a total transaction of $3,521.76.
Cardlytics Stock Down 3.1 %
CDLX stock opened at $7.83 on Wednesday. The firm has a 50 day moving average of $9.80 and a 200 day moving average of $9.56. The stock has a market capitalization of $381.95 million, a PE ratio of -1.77 and a beta of 1.65. The company has a quick ratio of 2.13, a current ratio of 2.13 and a debt-to-equity ratio of 1.30. Cardlytics, Inc. has a 52 week low of $5.69 and a 52 week high of $20.52.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on CDLX. Northland Securities initiated coverage on shares of Cardlytics in a research note on Tuesday, June 18th. They set an “outperform” rating and a $14.00 price target on the stock. Bank of America reaffirmed a “neutral” rating and issued a $11.00 price target on shares of Cardlytics in a research note on Thursday, June 20th. Northland Capmk raised shares of Cardlytics to a “strong-buy” rating in a research note on Tuesday, June 18th. Lake Street Capital increased their target price on shares of Cardlytics from $13.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $12.00 target price on shares of Cardlytics in a report on Tuesday, June 11th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.67.
Read Our Latest Stock Report on Cardlytics
Hedge Funds Weigh In On Cardlytics
A number of institutional investors have recently bought and sold shares of the business. Kent Lake Capital LLC purchased a new position in shares of Cardlytics during the 1st quarter valued at approximately $3,622,000. Blackstone Inc. acquired a new stake in Cardlytics during the 1st quarter worth $2,029,000. Perbak Capital Partners LLP acquired a new stake in Cardlytics during the 1st quarter worth $2,348,000. Price T Rowe Associates Inc. MD boosted its stake in Cardlytics by 6.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after purchasing an additional 1,774 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in Cardlytics during the 1st quarter worth $1,906,000. 68.10% of the stock is owned by hedge funds and other institutional investors.
Cardlytics Company Profile
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Recommended Stories
- Five stocks we like better than Cardlytics
- Dividend Capture Strategy: What You Need to Know
- RXO Shares Surge Following New Acquisition Deal
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.